HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

INTRODUCTION: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC)...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Juengel, Eva, Najafi, Ramin, Rutz, Jochen, Maxeiner, Sebastian, Makarevic, Jasmina, Roos, Frederik, Tsaur, Igor, Haferkamp, Axel, Blaheta, Roman A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://ncbi.nlm.nih.gov/pubmed/29299126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22454
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk